» Articles » PMID: 33359498

Low Expression of HIV Genes in Podocytes Accelerates the Progression of Diabetic Kidney Disease in Mice

Overview
Journal Kidney Int
Publisher Elsevier
Specialty Nephrology
Date 2020 Dec 28
PMID 33359498
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

With the widespread use combination antiretroviral therapy, there has been a dramatic decrease in HIV-associated nephropathy. However, although the patients living with HIV have low or undetectable viral load, the prevalence of chronic kidney disease (CKD) in this population remains high. Additionally, improved survival is associated with aging-related comorbidities such as diabetes and cardiovascular disease. A faster progression of CKD is associated with concurrent HIV infection and diabetes than with HIV infection or diabetes alone. To explore the potential pathogenic mechanisms that synergistically drive CKD progression by diabetes and HIV infection, we generated a new mouse model with a relatively low expression of HIV-1 proviral genes specifically in podocytes (pod-HIV mice) to better mimic the setting of kidney injury in patients living with HIV. While no apparent kidney phenotypes were observed at baseline in pod-HIV mice, the induction of mild diabetic kidney disease with streptozotocin led to significant worsening of albuminuria, glomerular injury, podocyte loss, and kidney dysfunction as compared to the mice with diabetes alone. Mechanistically, diabetes and HIV-1 synergistically increased the glomerular expression of microRNA-34a (miR-34a), thereby reducing the expression of Sirtuin-1 (SIRT1) deacetylase. These changes were also associated with increased acetylation and activation of p53 and p65 NF-κB and with enhanced expression of senescence and inflammatory markers. The treatment of diabetic pod-HIV mice with the specific Sirtuin-1 agonist BF175 significantly attenuated albuminuria and glomerulopathy. Thus, our study highlights the reduction in Sirtuin-1 as a major basis of CKD progression in diabetic patients living with HIV and suggests Sirtuin-1 agonists as a potential therapy.

Citing Articles

Pathogenesis of HIV-associated nephropathy in children and adolescents: taking a hard look 40 years later in the era of gene-environment interactions.

Ray P, Li J, Das J, Xu L, Yu J, Han Z Am J Physiol Renal Physiol. 2024; 327(6):F1049-F1066.

PMID: 39323389 PMC: 11687833. DOI: 10.1152/ajprenal.00208.2024.


Hyperactivation of p53 contributes to mitotic catastrophe in podocytes through regulation of the Wee1/CDK1/cyclin B1 axis.

Feng J, Xie L, Lu W, Yu X, Dong H, Ma Y Ren Fail. 2024; 46(2):2365408.

PMID: 38874119 PMC: 11182053. DOI: 10.1080/0886022X.2024.2365408.


Sirtuins in kidney diseases: potential mechanism and therapeutic targets.

Jin Q, Ma F, Liu T, Yang L, Mao H, Wang Y Cell Commun Signal. 2024; 22(1):114.

PMID: 38347622 PMC: 10860260. DOI: 10.1186/s12964-023-01442-4.


Mediation analysis of chronic kidney disease risk factors using kidney biomarkers in women living with HIV.

Edrosolan K, Shlipak M, Scherzer R, Estrella M, Gustafson D, Karim R AIDS. 2024; 38(6):813-824.

PMID: 38224361 PMC: 11025668. DOI: 10.1097/QAD.0000000000003839.


Viral Glomerulopathy.

Deoliveira M, Sikri H, Yu S, He J Glomerular Dis. 2023; 3(1):148-154.

PMID: 37901695 PMC: 10601964. DOI: 10.1159/000531434.


References
1.
Bosho D, Dube L, Mega T, Adare D, Tesfaye M, Eshetie T . Prevalence and predictors of metabolic syndrome among people living with human immunodeficiency virus (PLWHIV). Diabetol Metab Syndr. 2018; 10:10. PMC: 5822556. DOI: 10.1186/s13098-018-0312-y. View

2.
Brites-Alves C, Luz E, Netto E, Ferreira T, Diaz R, Pedroso C . Immune Activation, Proinflammatory Cytokines, and Conventional Risks for Cardiovascular Disease in HIV Patients: A Case-Control Study in Bahia, Brazil. Front Immunol. 2018; 9:1469. PMC: 6028567. DOI: 10.3389/fimmu.2018.01469. View

3.
Chen T, Cao Q, Wang Y, Harris D . M2 macrophages in kidney disease: biology, therapies, and perspectives. Kidney Int. 2019; 95(4):760-773. DOI: 10.1016/j.kint.2018.10.041. View

4.
Coppe J, Patil C, Rodier F, Sun Y, Munoz D, Goldstein J . Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 2008; 6(12):2853-68. PMC: 2592359. DOI: 10.1371/journal.pbio.0060301. View

5.
Zhong Y, Lee K, He J . SIRT1 Is a Potential Drug Target for Treatment of Diabetic Kidney Disease. Front Endocrinol (Lausanne). 2018; 9:624. PMC: 6199382. DOI: 10.3389/fendo.2018.00624. View